Patents by Inventor Mark Stearns

Mark Stearns has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11934847
    Abstract: An interactive user interface for receiving and displaying data is described. The interactive user interface may display data sets from a plurality of external applications and/or data sources. Received data sets may be compiled to form an interactive graphical unit, also called a “card,” that may be displayed in a format based upon that of the native external application of the received data sets. Cards may be grouped with other cards. A card may include a link which allows users to access the native external application of the card to make any desired modifications or changes.
    Type: Grant
    Filed: September 14, 2021
    Date of Patent: March 19, 2024
    Assignee: Palantir Technologies Inc.
    Inventors: Kelsey Falter, Joy Tao, Taylor Stearns, Tiffany Hsu, Barry McCardel, Mark Schafer, Andrew Bonventre
  • Patent number: 8206899
    Abstract: The invention relates to novel nucleic acids encoding a mammalian PCADM-1 gene, and proteins encoded thereby, whose expression is increased in certain diseases, disorders, or conditions, including, but not limited to, prostate cancer. The invention further relates to methods of detecting and treating prostate cancer, comprising modulating or detecting PCADM-1 expression and/or production and activity of PCADM-1 polypeptide. Further, the invention relates to novel assays for the identification of DNA-binding proteins and the double-stranded oligonucleotide sequences that specifically bind with them. Finally, the invention relates to DNAZYMs or DNA enzymes which specifically bind PCADM-1 mRNA to inhibit PCADM-1 gene expression and thereby destroy tumor cells and tumor tissue.
    Type: Grant
    Filed: January 21, 2011
    Date of Patent: June 26, 2012
    Assignee: Philadelphia Health and Education Corporation
    Inventors: Mark Stearns, Youji Hu, Min Wang
  • Publication number: 20110111979
    Abstract: The invention relates to novel nucleic acids encoding a mammalian PCADM-1 gene, and proteins encoded thereby, whose expression is increased in certain diseases, disorders, or conditions, including, but not limited to, prostate cancer, The invention further relates to methods of detecting and treating prostate cancer, comprising modulating or detecting PCADM-1 expression and/or production and activity of PCADM-1 polypeptide. Further, the invention relates to novel assays for the identification of DNA-binding proteins and the double-stranded oligonucleotide sequences that specifically bind with them. Finally, the invention relates to DNAZYMs or DNA enzymes which specifically bind PCADM-1 mRNA to inhibit PCADM-1 gene expression and thereby destroy tumor cells and tumor tissue.
    Type: Application
    Filed: January 21, 2011
    Publication date: May 12, 2011
    Inventors: Mark Stearns, Youji Hu, Min Wang
  • Patent number: 7939274
    Abstract: The invention relates to novel nucleic acids encoding a mammalian PCADM-1 gene, and proteins encoded thereby, whose expression is increased in certain diseases, disorders, or conditions, including, but not limited to, prostate cancer. The invention further relates to methods of detecting and treating prostate cancer, comprising modulating or detecting PCADM-1 expression and/or production and activity of PCADM-1 polypeptide. Further, the invention relates to novel assays for the identification of DNA-binding proteins and the double-stranded oligonucleotide sequences that specifically bind with them. Finally, the invention relates to DNAZYMs or DNA enzymes which specifically bind PCADM-1 mRNA to inhibit PCADM-1 gene expression and thereby destroy tumor cells and tumor tissue.
    Type: Grant
    Filed: May 18, 2010
    Date of Patent: May 10, 2011
    Assignee: Philadelphia Health and Education Corporation
    Inventors: Mark Stearns, Youji Hu, Min Wang
  • Patent number: 7790861
    Abstract: The invention relates to novel nucleic acids encoding a mammalian PCADM-1 gene, and proteins encoded thereby, whose expression is increased in certain diseases, disorders, or conditions, including, but not limited to, prostate cancer. The invention further relates to methods of detecting and treating prostate cancer, comprising modulating or detecting PCADM-1 expression and/or production and activity of PCADM-1 polypeptide. Further, the invention relates to novel assays for the identification of DNA-binding proteins and the double-stranded oligonucleotide sequences that specifically bind with them. Finally, the invention relates to DNAZYMs or DNA enzymes which specifically bind PCADM-1 mRNA to inhibit PCADM-1 gene expression and thereby destroy tumor cells and tumor tissue.
    Type: Grant
    Filed: May 7, 2002
    Date of Patent: September 7, 2010
    Assignee: Philadelphia Health and Education Corporation
    Inventors: Mark Stearns, Youji Hu, Min Wang
  • Publication number: 20100221753
    Abstract: The invention relates to novel nucleic acids encoding a mammalian PCADM-1 gene, and proteins encoded thereby, whose expression is increased in certain diseases, disorders, or conditions, including, but not limited to, prostate cancer. The invention further relates to methods of detecting and treating prostate cancer, comprising modulating or detecting PCADM-1 expression and/or production and activity of PCADM-1 polypeptide. Further, the invention relates to novel assays for the identification of DNA-binding proteins and the double-stranded oligonucleotide sequences that specifically bind with them. Finally, the invention relates to DNAZYMs or DNA enzymes which specifically bind PCADM-1 mRNA to inhibit PCADM-1 gene expression and thereby destroy tumor cells and tumor tissue.
    Type: Application
    Filed: May 18, 2010
    Publication date: September 2, 2010
    Inventors: MARK STEARNS, YOUJI HU, MIN WANG
  • Patent number: 7754435
    Abstract: The invention relates to novel nucleic acids encoding a mammalian PCADM-1 gene, and proteins encoded thereby, whose expression is increased in certain diseases, disorders, or conditions, including, but not limited to, prostate cancer. The invention further relates to methods of detecting and treating prostate cancer, comprising modulating or detecting PCADM-1 expression and/or production and activity of PCADM-1 polypeptide. Further, the invention relates to novel assays for the identification of DNA-binding proteins and the double-stranded oligonucleotide sequences that specifically bind with them. Finally, the invention relates to DNAZYMs or DNA enzymes which specifically bind PCADM-1 mRNA to inhibit PCADM-1 gene expression and thereby destroy tumor cells and tumor tissue.
    Type: Grant
    Filed: November 2, 2004
    Date of Patent: July 13, 2010
    Assignee: Philadelphia Health and Education Corporation
    Inventors: Mark Stearns, Youji Hu, Min Wang
  • Publication number: 20070099214
    Abstract: The invention relates to nucleic acids encoding a mammalian ABCA5 gene, and proteins encoded thereby, whose expression is increased in certain diseases, disorders, or conditions, including, but not limited to, PIN. Further, the invention relates to diagnostic assays for identifying the DNA-binding protein ABCA5 (also known as PIN-1). The invention also relates to oligonucleotide sequence(s) or antibodies that specifically bind with ABCA5 or variants thereof.
    Type: Application
    Filed: September 1, 2006
    Publication date: May 3, 2007
    Applicant: PHILADELPHIA HEALTH & EDUCATION CORPORATION d/b/a Drexel University College of Medicine
    Inventors: Mark Stearns, Youji Hu, Min Wang
  • Publication number: 20050142592
    Abstract: The invention relates to novel nucleic acids encoding a mammalian PCADM-1 gene, and proteins encoded thereby, whose expression is increased in certain diseases, disorders, or conditions, including, but not limited to, prostate cancer. The invention further relates to methods of detecting and treating prostate cancer, comprising modulating or detecting PCADM-1 expression and/or production and activity of PCADM-1 polypeptide. Further, the invention relates to novel assays for the identification of DNA-binding proteins and the double-stranded oligonucleotide sequences that specifically bind with them. Finally, the invention relates to DNAZYMs or DNA enzymes which specifically bind PCADM-1 mRNA to inhibit PCADM-1 gene expression and thereby destroy tumor cells and tumor tissue.
    Type: Application
    Filed: November 2, 2004
    Publication date: June 30, 2005
    Inventors: Mark Stearns, Youji Hu, Min Wang
  • Publication number: 20030207339
    Abstract: The present invention provides a cancer marker protein, PCAM-1, and polynucleotides which identify and encode this protein. Detection of this marker is useful in diagnosing and prognosticating cancer in a patient. Also provided are expression vectors and host cells for expression of PCAM-1 as well as antibodies raised against the PCAM-1 protein. In addition, a Monte Carlo-like screening assay for identification of specific 8 mer sequences which selectively bind proteins in a crude extrract of tissues, cells or other biological fluids is provided.
    Type: Application
    Filed: March 15, 2002
    Publication date: November 6, 2003
    Applicant: Philadelphia Health and Education Corporation
    Inventors: Mark Stearns, Youji Hu
  • Publication number: 20030100033
    Abstract: The invention relates to novel nucleic acids encoding a mammalian PCADM-1 gene, and proteins encoded thereby, whose expression is increased in certain diseases, disorders, or conditions, including, but not limited to, prostate cancer. The invention further relates to methods of detecting and treating prostate cancer, comprising modulating or detecting PCADM-1 expression and/or production and activity of PCADM-1 polypeptide. Further, the invention relates to novel assays for the identification of DNA-binding proteins and the double-stranded oligonucleotide sequences that specifically bind with them. Finally, the invention relates to DNAZYMs or DNA enzymes which specifically bind PCADM-1 mRNA to inhibit PCADM-1 gene expression and thereby destroy tumor cells and tumor tissue.
    Type: Application
    Filed: May 7, 2002
    Publication date: May 29, 2003
    Inventors: Mark Stearns, Youji Hu, Min Wang
  • Publication number: 20020042062
    Abstract: The invention relates to novel nucleic acids encoding a mammalian PCAM-1 gene, and proteins encoded thereby, whose expression is increased in certain diseases, disorders, or conditions, including, but not limited to, prostate cancer. The invention further relates to methods of detecting and treating prostate cancer, comprising modulating or detecting PCAM-1 expression and/or production and activity of PCAM-1 polypeptide. Further, the invention relates to novel assays for the identification of DNA-binding proteins and the double-stranded oligonucleotide sequences that specifically bind with them.
    Type: Application
    Filed: March 21, 2001
    Publication date: April 11, 2002
    Inventors: Mark Stearns, Youji Hu, Min Wang